Currently, it is more difficult to imagine a roadmap to therapy by targeting a specific pathogenic pathway induced by DUX4, largely because there is no method to prioritize the multiple pathways that might lead to the FSHD pathophysiology. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.